I-Mab (IMAB)
| Market Cap | 3.85B |
| Revenue (ttm) | 4.29M |
| Net Income (ttm) | -212.14M |
| Shares Out | 70.50M |
| EPS (ttm) | -287.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $54.67 |
| Previous Close | $51.84 |
| Change ($) | 2.83 |
| Change (%) | 5.46% |
| Day's Open | 52.75 |
| Day's Range | 51.00 - 54.86 |
| Day's Volume | 169,815 |
| 52-Week Range | 10.63 - 57.77 |
SHANGHAI and GAITHERSBURG, Md., Dec. 23, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and comme...
SHANGHAI and GAITHERSBURG, Md., Dec. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commer...
SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commer...
SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commer...
In a GuruFocus article on Nov. 17, I took a look at three of the nine public Chinese biotechnology companies that are projected to become major international competitors in the coming years, a...
Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic De...
SHANGHAI and GAITHERSBURG, Md., Nov. 13, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and comme...
SHANGHAI and GAITHERSBURG, Md., Nov. 11, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and comme...
SHANGHAI and GAITHERSBURG, Md., Nov. 9, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commer...
SHANGHAI, China, and GAITHERSBURG, MD., Oct. 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development a...
SHANGHAI and GAITHERSBURG, Md., Oct. 27, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and comme...
PLANEGG/MUNICH, Germany and SHANGHAI, China, Sept. 17, 2020 /PRNewswire/ -- MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab (Nasdaq: IMAB) today jointly a...
I-Mab (IMAB) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Companies in the news are: IMAB, LMPX, DPW, ANPC
Shanghai's I-Mab out-licensed ex-China rights for lemzoparlimab, its anti-CD47 mAb, to AbbVie in a blockbuster $2 billion agreement.
I-Mab (IMAB) is seeing gains to IMAB stock on Friday after the biopharma company announced news of a deal with AbbVie (ABBV).
The deal could be the largest-ever out-licensing agreement by a Chinese biotech.
Shares of I-Mab IMAB, +0.47% soared 17% in premarket trading Friday toward a record high, after the China-based biotechnology company announced a collaboration agreement with AbbVie Inc.
SHANGHAI and GAITHERSBURG, Md., Sept. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and comme...
NORTH CHICAGO, Ill., and SHANGHAI, Sept.
Shares of Chinese biopharmaceutical company I-Mab (NASDAQ:IMAB) continued to impress following the recent half-year results for the period ended June 30.
I-Mab's (IMAB) CEO Joan Huaqiong Shen on Q2 2020 Results - Earnings Call Transcript
Positive preliminary clinical trial results for lemzoparlimab (TJC4) demonstrate a differentiated drug profile in safety and pharmacokinetics in cancer patients Joined the global effort agains...
SHANGHAI and GAITHERSBERG, Md., Aug. 17, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and comme...
SHANGHAI and GAITHERSBERG, Md., Aug. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commer...
SHANGHAI and GAITHERSBERG, Md., July 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and comme...
SHANGHAI and GAITHERSBURG, Md., July 15, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and comme...
SHANGHAI and GAITHERSBURG, Md., June 12, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and comme...
About IMAB
I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. It is developing Felzartamab (TJ202), a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin (TJ101), a long-acting human growth hormone that has completed Phase II clinical trials to treat pediatric growth hormone deficiency; and Olamkicept... [Read more...]
| Industry Biotechnology | IPO Date Jan 17, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol IMAB |
Financial Performance
In 2019, I-Mab's revenue was 30.00 million, a decrease of -44.22% compared to the previous year's 53.78 million. Losses were -1.45 billion, 260.4% more than in 2018.
Analyst Forecasts
According to 7 analysts, the average rating for I-Mab stock is "Strong Buy." The 12-month stock price forecast is 54.42, which is a decrease of -0.46% from the latest price.